Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $807.5K in total
- 3
- 13F holdersQ2 2026, +15 vs. previous quarter
- 95
- 13F valueReported value at the end of Q2 2026
- $576.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MNPR, Q2 2026
No superinvestor reported holding MNPR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Monopar Therapeutics insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 (view filing)8:18 PM ET | Aug 26 | 2 days | Tsuchimoto Kim RDirector | SSale | −4.09K | $111.39 | −$455.6K | −100.0%0 after | Amended6 lots10b5-1 |
| Aug 28, 2026 (view filing)7:41 PM ET | Aug 25 | 3 days | Anderson RaymondDirector | SSale | −3.14K | $111.98 | −$351.8K | −36.9%5.37K after | Amended3 lots10b5-1 |
| Aug 27, 2026 (view filing)7:29 PM ET | Aug 26 | 1 day | Rioux PatriceOther: Acting Chief Medical Officer | SSale | −1 | $111.26 | −$111.26 | 0.0%5.07K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Vu Quan AnhChief Financial Officer | PPurchase | +1.50K | $69.95 | +$104.9K | New position1.50K after | |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Klausner Arthur JDirector | SSale | −5.12K | $67.15 | −$343.9K | −36.9%8.76K after | 2 lots |
| Sep 26, 2025 (view filing)3:53 PM ET | Sep 24 | 2 days | Robinson Chandler and 4 othersChief Executive Officer | SSale | −550.2K | $63.61 | −$35.0M | −66.9%272.0K after | |
| Jul 16, 2025 (view filing)9:06 PM ET | Jul 14 | 2 days | Tsuchimoto Kim RDirector | SSale | −8.90K | $40.00 | −$356.2K | −43.7%11.5K after | |
| Jul 16, 2025 (view filing)9:03 PM ET | Jul 14 | 2 days | Starr Christopher MDirector | SSale | −16.8K | $40.00 | −$672.0K | −76.5%5.17K after | |
| Jul 16, 2025 (view filing)9:02 PM ET | Jul 14 | 2 days | Robinson ChandlerChief Executive Officer | SSale | −16.8K | $40.00 | −$672.0K | −18.6%73.5K after | |
| Apr 4, 2025 (view filing)7:27 PM ET | Apr 2 | 2 days | Robinson Chandler and 4 othersChief Executive Officer | SSale | −33.3K | $35.00 | −$1.17M | −3.9%822.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Monopar Therapeutics at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,312,129 | $121.7M | 0.05% | +1,312,129 | New |
| Ra Capital Management, L.P. | 667,207 | $61.8M | 0.54% | 00.0% | Unchanged |
| BlackRock, Inc. | 348,819 | $32.3M | 0.00% | +32,252+10.2% | Added |
| Deerfield Management Company, L.P. (Series C) | 323,745 | $30.0M | 0.31% | 00.0% | Unchanged |
| Saturn V Capital Management LLC | 311,976 | $28.9M | 4.14% | −33,650−9.7% | Reduced |
| Siren, L.L.C. | 270,118 | $25.0M | 0.51% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 217,595 | $20.1M | 0.95% | −46,683−17.7% | Reduced |
| Polar Capital Holdings Plc | 214,469 | $19.9M | 0.06% | −12,057−5.3% | Reduced |
| Vanguard Capital Management LLC | 209,711 | $19.4M | 0.00% | −8,752−4.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 209,195 | $19.4M | 0.03% | −100,000−32.3% | Reduced |